The new RDT technology is especially useful for low- and middle-income countries (LMICs), as it is easy to use in health facilities without requiring additional equipment. Tests are highly sensitive and can generate results within 20 minutes. Codix Bio will initially focus on producing RDTs for HIV, but the technology can also be used for manufacturing tests for malaria and syphilis, among others. It can also be quickly adapted to other diseases, which will prove valuable during health emergencies and pandemics, contributing to improvements in health security and equity.
“We are delighted to have signed this first sublicense agreement for RDTs with Codix Bio. Today marks a major step forward in diversifying diagnostic production and ensuring access where it is needed most,” said Charles Gore, Executive Director of the Medicines Patent Pool. “It shows how voluntary licensing and coordinated technology transfer can empower manufacturers in LMICs, ultimately helping reshape global supply chains to become more equitable and resilient.”
A new beginning for HTAP
“The announcement of this sublicensing agreement with Codix Bio marks an important milestone in our partnership with WHO and MPP. By coupling the technology transfer with coordinated support, this initiative not only helps Codix Bio respond to health priorities in Nigeria and the region – it also demonstrates a collaborative model for building sustainable and self-reliant local manufacturing capacity,” said Hyo-Keun Lee, Vice Chairman of SD Biosensor, Inc. “We are proud that our highly adaptable and reliable rapid diagnostic testing technology will contribute to strengthening regional manufacturing ecosystems and expanding equitable access to diagnostics.”
HTAP will coordinate support from across WHO and its partners, covering areas such as workforce development, regulatory compliance and product uptake. It is also continuing with evaluations for a potential second sublicensee for this technology transfer.
"Africa CDC welcomes this partnership as a concrete example of what regional health security can look like. Building diagnostic manufacturing capacity within the continent improves pandemic response and helps build African health sovereignty. We are pleased to see Africa CDC’s strategic direction reflected in this initiative, and we stand ready to support its implementation through coordination and technical assistance,” said Dr Abebe Bayih, lead of the Platform for Harmonized African Health Manufacturing (PHAH).
Note to editors
About WHODedicated to the well-being of all people and guided by science, the World Health Organization leads and champions global efforts to give everyone, everywhere an equal chance at a safe and healthy life. We are the UN agency for health that connects nations, partners and people on the front lines in 150+ locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to promote health, keep the world safe and serve the vulnerable. www.who.int
Read More Details
Finally We wish PressBee provided you with enough information of ( WHO and Medicines Patent Pool announce sublicensing agreement for rapid diagnostic test technology )
Also on site :